- Raised $16M funding round led by Marius Nacht, May 2022
- Raised $1.1M grant, May 2019
- Raised $1M funding round, Nov 2009
About
BioGenCell is developing cellular therapies designed to treat blood flow problems in the limbs, a side effect of diabetes and heart disease. The company's technology creates autologous cells, derived from the patients themselves, to repair themselves. BioGenCell's lead product, BC1, uses the company's technology to treat blood vessel insufficiency, which can cause multiple organ failure in diabetic patients. Derived from the patient's own adult stem cells, BioGenCell's easy-to-use and cost-effective therapies can regenerate damaged tissues, with the eventual goal of treating a wide range of degenerative diseases including diabetes, heart failure, stroke, blindness, cancer, and immunological diseases. BioGenCell's patented technology platform provides a comprehensive solution for most aspects of cellular therapy and supports rapid manufacturing and long-term storage (biobanking) of therapeutic cellular products for use in patient treatment.
Funding history · 4 rounds · $18.4M total
Q&A
- What is BioGenCell's primary focus?
- BioGenCell is developing cellular therapies to treat blood flow problems in the limbs, which are often side effects of diabetes and heart disease. Their technology uses autologous cells derived from patients to facilitate self-repair.
- What is BioGenCell's lead product?
- BioGenCell's lead product, BC1, is designed to treat blood vessel insufficiency, a condition that can lead to multiple organ failure in diabetic patients.
- What is the total funding BioGenCell has raised to date?
- BioGenCell has raised a total of $18,350,000 in funding.
- When was BioGenCell's most recent funding round and who was the lead investor?
- BioGenCell's most recent funding round occurred in May 2022, raising $16,000,000 with Marius Nacht as the lead investor.
- How many employees does BioGenCell have?
- BioGenCell has 11-50 employees.
- When was BioGenCell founded?
- BioGenCell was founded in December 2008.
- Does BioGenCell hold any patents?
- Yes, BioGenCell holds one patent related to its technology platform.
- Who are the co-founders of BioGenCell?
- The co-founders of BioGenCell are Yael Porat (CEO), Eyal Peleg (CFO), and Michael Belkin (CSO).
Team · 3
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | biogencell.net |
|---|---|
| linkedin.com/company/69232576 | |
| facebook.com/www.BioGenCell.net |
Identifiers & details
| Founded | 2008-12 |
|---|---|
| Employees (exact) | 15 |
Radar intelligence
Patents
| EPO | 5 |
|---|
Publications (Crossref)
| Works | 3 |
|---|
Web history (Wayback)
| Domain | biogencell.net |
|---|
Certificate / subdomain footprint
| Subdomains | 8 |
|---|